Paritaprevir

From Wikipedia, the free encyclopedia
  (Redirected from ABT-450)
Jump to: navigation, search
Paritaprevir
Paritaprevir.svg
Systematic (IUPAC) name
(2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
Clinical data
Identifiers
PubChem CID 45110509
ChemSpider 32700634
ChEBI CHEBI:85188 YesY
Synonyms Veruprevir; ABT-450
Chemical data
Formula C40H43N7O7S
765.88 g/mol

Paritaprevir (ABT-450) is an acylsulfonamide[1] inhibitor of the NS3-4A serine protease[2] manufactured by Abbott Laboratories[3] that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1.[4] Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.[5]p. 248

Paritaprevir is a component of Viekira Pak.

References[edit]

  1. ^ Seng-Lai Tan and Yupeng He, ed. (2011). Hepatitis C: antiviral drug discovery and development. Norfolk: Caister academic press. p. 210. ISBN 9781904455783. Retrieved 28 April 2014. 
  2. ^ Donald Jensen, Nancy Reau, ed. (2013). Hepatitis C. New York: Oxford University Press. p. 144. ISBN 9780199844296. Retrieved 28 April 2014. 
  3. ^ "Abbott Announces Phase 3 Hepatitis C Program Details". Abbott company website. Abbott Laboratories. Retrieved 28 April 2014. 
  4. ^ Kowdley, Kris V.; Lawitz, Eric; Poordad, Fred; Cohen, Daniel E.; Nelson, David R.; Zeuzem, Stefan; Everson, Gregory T.; Kwo, Paul; Foster, Graham R.; Sulkowski, Mark S.; Xie, Wangang; Pilot-Matias, Tami; Liossis, George; Larsen, Lois; Khatri, Amit; Podsadecki, Thomas; Bernstein, Barry (2014). "Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1". New England Journal of Medicine 370 (3): 222–232. doi:10.1056/NEJMoa1306227. ISSN 0028-4793. 
  5. ^ Stefan Mauss et al., eds. (2013). Hepatology 2013 a clinical textbook (PDF) (4th ed. ed.). Düsseldorf: Flying Publisher. ISBN 978-3-924774-90-5. Retrieved 28 April 2014.